A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).

Completed · Phase 1

Conditions studied: Nausea and Vomiting, Chemotherapy-Induced

In brief

This study will examine what the body does while taking GW679769 alone and together with rifampin in healthy adult subjects.

Key facts

Study ID

NCT00405080

Run by

GlaxoSmithKline

People needed

12

Starts

2006-11-11

Expected to finish

2007-01-05

Last updated by the study team

2017-09-12

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• healthy
• female subjects who cannot become pregnant
• able to swallow and keep down oral medication
• can understand and follow the protocol requirements and instructions

You may not qualify if…

• smokes at least 4 packs per day in the past 12 months
• use of prescription or non-prescription drug(s)
• herbal or dietary supplements or vitamins with 14 days prior to first dose of study medication
• a clinically relevant abnormality medical condition or circumstance making the subject unsuitable for the study per the study doctor
• blood donation in excess of 1 pint within 56 days before dosing of medication
• iron deficient
• history or drug allergy of study medication
• history of drug or alcohol abuse or dependency within the past 6 months
• subjects cannot use any nicotine-containing products within the last 6 months
• positive for HIV, Hepatitis B or C
• active peptic ulcer disease
• uncontrolled nausea and vomiting
• active infection
• heart failure
• female who is lactating
• female who has a positive pregnancy test

Where it is running

• GSK Investigational Site — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.